IQVIA™ Real-World Insights Bibliography

Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal
Author(s): Max Schlueter, Amélie Beaudet, Evan Davies, Binu Gurung, Andreas Karabis
Affiliations(s): IQVIA, 210 Pentonville Road, London, N1 9JY; IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, Netherlands; Department of Statistical Science, University College London, London, WC1E 6BT, UK.
Publication(s): 
Document Type(s): Article,
Countries: 
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Methodology, Rare Diseases,
2020
  L:
A:
English
Literature Review, Review,
  Add to report
 
 
Cost-utility model for 2nd generation treatment of chronic HCV in general population: impact of EASL recommendations in 2016 and 2018
Author(s): Nat?lia Pascual-Argent? (1,2); Carlos Crespo (1,3); Laura Planellas (4); M?riam Solozabal (4), N?ria Perulero (4); Jaume Puig-Junoy (1,2)
Affiliations(s): (1) UPF Barcelona School of Management; (2) Dept. Econom?a y Empresa ? CRES UPF; (3) Universitat de Barcelona; (4) HEOR-RWE, IQVIA Spain
Publication(s):  XXXIX Jornadas de Econom?a de la Salud. Albacete, 12 al 14 de junio de 2019
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Health economics, Infectious disease,
2019
  L:
A:
Spanish
Clinical setting: hospital, Cost effectiveness,
  Add to report
 
 
Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden
Author(s): Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong
Affiliations(s): IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden
Publication(s):  ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark
Document Type(s): Poster,
Countries: Denmark, Finland, Nordic, Norway, Sweden,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2019
  L:
A:
English
Review,
  Add to report
 
 
LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION.
Author(s): Allou A*, Carette J*, Minacori R*, Touahmia S*, Bourguignon S*, Troubat A*, Maurel F*
Affiliations(s): IQVIA France - RWI
Publication(s):  ISPOR 2018
Document Type(s): Poster,
Countries: France,
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Health economics, Hematology,
2018
  L:
A:
English
Cost effectiveness, Market impact, Review,
  Add to report
 
 
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE.
Author(s): Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles
Affiliations(s): RWI IQVIA France
Publication(s):  ISPOR 2018
Document Type(s): Poster,
Countries: France,
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases,
2018
  L:
A:
English
Cost effectiveness, Pricing & Reimbursement, Willingness to pay,
  Add to report
 
 
ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN France
Author(s): Vasilescu L., Faller M., Allou A.
Affiliations(s): IQVIA France - RWI
Publication(s):  ISPOR 2018
Document Type(s): Poster,
Countries: France,
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Methodology,
2018
  L:
A:
English
Literature Review, Public Health, Review,
  Add to report
 
 
A COST-EFFECTIVENESS ANALYSIS COMPARING THE ORIGINATOR RECOMBINANT HUMAN ALFA TO THEIR BIOSIMILARS FOLLITROPIN ALFA FOR THE TREATMENT OF INFERTILITY.
Author(s): Ravonimbola H(1), Petrica N (1), Maurel F(1), Murphy C(2), Doré C(2), Fresneau L(2),
Affiliations(s): (1) QuintilesIMS, Paris France (2) Merck Serono, France
Publication(s):  ISPOR 2017
Document Type(s): Poster,
Countries: France,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2017
  L:
A:
English
Cost effectiveness, Literature Review, Randomised controlled trial,
  Add to report
 
 
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS
Author(s): Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F*
Affiliations(s): IQVIA France - RWI
Publication(s):  ISPOR 2017
Document Type(s): Poster,
Countries: Australia, Canada, France, UK,
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2017
  L:
A:
English
Cost effectiveness, Literature Review, Pricing & Reimbursement, Review,
  Add to report
 
 
How market access will play out
Author(s): Bosco j, Dreyer N
Affiliations(s): Quintiles Real World and late phase research
Publication(s):  Managed healthcare executive
Document Type(s): 
Countries: 
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2016
  L:
A:
English
RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
RiGOR: a prospective observational study comparing the effectiveness of treatment strategies for open-angle glaucoma.
Author(s): Coleman AL1,2, Lum FC1, Velentgas P3, Campion D3, Su Z3, Gliklich RE4; RiGOR Study Group.
Affiliations(s): 1H. Dunbar Hoskins Jr, MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 2Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA 02139, USA.
Publication(s):  Journal of Comparative Effectiveness. Jan 2016; 5(1), 65-78
Document Type(s): Article,
Countries: 
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2016
  L:
A:
English
Observational study, Prospective study, RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
 1 of 4 Next Page Last Page